Herrmann Ken
CIK: 0002049757
Associated companies
Transaction History
| AKTS | ▲ Buy | Option Exercise | 3,506 | $280 | 7/20/2026 | View on chart |
| AKTS | ▲ Buy | Option Exercise | 1,350 | $3K | 7/20/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 3,506 | $86K | 7/20/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 1,350 | $33K | 7/20/2026 | View on chart |
| AKTS | ▲ Buy | Option Exercise | 3,065 | $245 | 7/17/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 3,065 | $77K | 7/17/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.